IDO1 and neoplasm: However, IDO1 inhibitors also face challenges, such as poor water solubility, low bioavailability, and lack of tumor specificity.[16] Additionally, combination therapies often require different drugs to be effectively delivered to the tumor region in a spatiotemporally controlled manner.